Penetrium Bioscience Inc. (KOSDAQ:187660)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,510
-750 (-5.66%)
At close: Apr 28, 2026
630.30%
Market Cap 685.09B
Revenue (ttm) 9.74B
Net Income (ttm) -20.10B
Shares Out 54.76M
EPS (ttm) -475.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,578,057
Average Volume 3,517,166
Open 13,560
Previous Close 13,260
Day's Range 12,430 - 13,600
52-Week Range 1,118 - 21,500
Beta 3.02
RSI 47.63
Earnings Date Mar 30, 2026

About Penetrium Bioscience

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance serv... [Read more]

Industry Commercial Physical and Biological Research
Founded 2003
Employees 160
Stock Exchange KOSDAQ
Ticker Symbol 187660
Full Company Profile

Financial Performance

In 2024, Penetrium Bioscience's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.

Financial Statements

News

There is no news available yet.